NYSE American - Delayed Quote USD
Channel Therapeutics Corporation (CHRO)
1.2265
-0.1135
(-8.47%)
At close: June 13 at 3:54:52 PM EDT
1.2200
-0.01
(-0.53%)
After hours: June 13 at 7:56:13 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
7,471.4440
7,571.4490
6,862.2840
2,318.1590
838.9960
Operating Income
-7,471.4440
-7,571.4490
-6,862.2840
-2,318.1590
-838.9960
Net Non Operating Interest Income Expense
-291.6790
-786.3930
-518.5090
-140.4300
-0.2530
Other Income Expense
--
402.5040
--
--
243.8620
Pretax Income
-7,360.6190
-7,955.3380
-7,380.7930
-2,458.5890
-595.3870
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-7,360.6190
-7,955.3380
-7,380.7930
-2,458.5890
-595.3870
Diluted NI Available to Com Stockholders
-7,360.6190
-7,955.3380
-7,380.7930
-2,458.5890
-595.3870
Basic EPS
-1.20
--
-1.28
-0.26
-0.10
Diluted EPS
-1.20
--
-1.28
-0.26
-0.10
Basic Average Shares
5,933.7070
--
5,767.5250
9,286.9280
5,767.5250
Diluted Average Shares
5,933.7070
--
5,767.5250
9,286.9280
5,767.5250
Total Operating Income as Reported
-7,471.4440
-7,571.4490
-6,862.2840
-2,318.1590
-838.9960
Total Expenses
7,471.4440
7,571.4490
6,862.2840
2,318.1590
838.9960
Net Income from Continuing & Discontinued Operation
-7,360.6190
-7,955.3380
-7,380.7930
-2,458.5890
-595.3870
Normalized Income
-7,723.7100
-8,318.4290
-7,380.7930
-2,458.5890
-839.2490
Interest Expense
291.6790
786.3930
518.5090
140.4300
0.2530
Net Interest Income
-291.6790
-786.3930
-518.5090
-140.4300
-0.2530
EBIT
-7,068.9400
-7,168.9450
-6,862.2840
-2,318.1590
-595.1340
EBITDA
-7,068.9400
-7,168.9450
-6,862.2840
-2,318.1590
-595.1340
Net Income from Continuing Operation Net Minority Interest
-7,360.6190
-7,955.3380
-7,380.7930
-2,458.5890
-595.3870
Total Unusual Items Excluding Goodwill
363.0910
363.0910
0
0
243.8620
Total Unusual Items
363.0910
363.0910
0
0
243.8620
Normalized EBITDA
-7,432.0310
-7,532.0360
-6,862.2840
-2,318.1590
-838.9960
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 2/16/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GANX Gain Therapeutics, Inc.
1.7300
-3.89%
KAPA Kairos Pharma, Ltd.
0.5200
-8.77%
MRPI Mera Pharmaceuticals, Inc.
0.0001
0.00%
QNRX Quoin Pharmaceuticals, Ltd.
8.38
-0.12%
GRI GRI Bio, Inc.
1.3000
-7.14%
ASPHF Ascentage Pharma Group International
5.83
0.00%
VOR Vor Biopharma Inc.
0.1821
-12.03%
RADX Radiopharm Theranostics Limited
5.05
-5.25%
ENVB Enveric Biosciences, Inc.
1.2100
-2.42%
CDT Conduit Pharmaceuticals Inc.
2.3300
-5.67%